These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27658564)

  • 1. Follow-up after surgery for hemorrhagic AMD.
    Garcia D; Mahieu L; Soubrane G; Salmon L; Renouvin A; Pagot-Mathis V; Matonti F; Soler V
    J Fr Ophtalmol; 2016 Oct; 39(8):661-667. PubMed ID: 27658564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.
    Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY
    Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.
    Tranos P; Tsiropoulos GN; Koronis S; Vakalis A; Asteriadis S; Stavrakas P
    Int Ophthalmol; 2021 Dec; 41(12):4037-4046. PubMed ID: 34331185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration.
    Gok M; Karabaş VL; Aslan MS; Kara Ö; Karaman S; Yenihayat F
    Indian J Ophthalmol; 2017 Jun; 65(6):482-487. PubMed ID: 28643713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of macular hematoma complicating AMD by vitrectomy, subretinal r-TPA injection, intravitreal injection of bevacizumab combined with gas tamponade: Report of 4 cases].
    Abboud M; Benzerroug M; Milazzo S
    J Fr Ophtalmol; 2017 Feb; 40(2):133-137. PubMed ID: 28189348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
    Mayer WJ; Hakim I; Haritoglou C; Gandorfer A; Ulbig M; Kampik A; Wolf A
    Acta Ophthalmol; 2013 May; 91(3):274-8. PubMed ID: 21952010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Fassbender JM; Sherman MP; Barr CC; Schaal S
    Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for visual acuity improvement after treatment of submacular hemorrhage secondary to exudative age-related macular degeneration.
    Barayev E; Tiosano A; Zlatkin R; Elul R; Dotan A; Hadayer A; Gal-Or O; Ehrlich R
    Eur J Ophthalmol; 2024 May; 34(3):825-833. PubMed ID: 37715632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
    Boulanger-Scemama E; Sayag D; Ha Chau Tran T; Quaranta-El Maftouhi M; Rumen F; Creuzot-Garcher C; Blanco Garavito R; Jung C; Souied E
    J Fr Ophtalmol; 2016 Oct; 39(8):668-674. PubMed ID: 27609025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
    Bodénès F; Massé H; Lebreton O; Weber M
    J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy.
    Matsunaga DR; Su D; Sioufi K; Obeid A; Wibbelsman T; Ho AC; Regillo CD
    Ophthalmol Retina; 2021 Apr; 5(4):342-347. PubMed ID: 32763426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator.
    Kimura S; Morizane Y; Hosokawa M; Shiode Y; Kawata T; Doi S; Matoba R; Hosogi M; Fujiwara A; Inoue Y; Shiraga F
    Am J Ophthalmol; 2015 Apr; 159(4):683-9. PubMed ID: 25555798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.
    Treumer F; Klatt C; Roider J; Hillenkamp J
    Br J Ophthalmol; 2010 Jan; 94(1):48-53. PubMed ID: 19946027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
    Boiché M; Angioi-Duprez K; Conart JB; Berrod JP
    J Fr Ophtalmol; 2020 Jan; 43(1):43-50. PubMed ID: 31870667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.